Lisa Ottenhoff Msw Csw Acsw | |
391 S Shore Dr Ste 214 Battle Creek MI 49014 | |
(269) 964-0153 | |
(855) 877-5812 |
Full Name | Lisa Ottenhoff Msw Csw Acsw |
---|---|
Speciality | Social Worker |
Location | 391 S Shore Dr Ste 214, Battle Creek, Michigan |
Authorized Official Name and Position | Lisa Ottenhoff (OWNER) |
Authorized Official Contact | 2699640153 |
Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
Mailing Address | Practice Location Address |
---|---|
Lisa Ottenhoff Msw Csw Acsw 391 S Shore Dr Ste 214 Battle Creek MI 49014-5446 Ph: (269) 964-0153 | Lisa Ottenhoff Msw Csw Acsw 391 S Shore Dr Ste 214 Battle Creek MI 49014 Ph: (269) 964-0153 |
NPI Number | 1306193602 |
---|---|
Provider Enumeration Date | 08/07/2012 |
Last Update Date | 06/11/2021 |
Certification Date | 06/11/2021 |
Medicare PECOS PAC ID | 8123305802 |
---|---|
Medicare Enrollment ID | O20170505001608 |
News Archive
Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.
Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.
Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.
The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.
› Verified 4 days ago
Identifier | Type | State | Issuer |
---|---|---|---|
1306193602 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1041C0700X | Social Worker - Clinical | 6801065659 (Michigan) | Primary |
Provider Name | Jerry D Gillette |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1831224682 PECOS PAC ID: 7315916434 Enrollment ID: I20040927000434 |
News Archive
Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.
Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.
Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.
The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.
› Verified 4 days ago
Provider Name | Marilyn C Strobel |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1306954797 PECOS PAC ID: 2769489699 Enrollment ID: I20061107000039 |
News Archive
Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.
Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.
Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.
The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.
› Verified 4 days ago
Provider Name | Lisa Y Ottenhoff |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1083613624 PECOS PAC ID: 9234328584 Enrollment ID: I20110118000994 |
News Archive
Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.
Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.
Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.
The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.
› Verified 4 days ago
Provider Name | Jean Concannon |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1912446139 PECOS PAC ID: 6901181585 Enrollment ID: I20170322000615 |
News Archive
Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.
Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.
Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.
The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.
› Verified 4 days ago
Provider Name | Marrit Shiery |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1356893960 PECOS PAC ID: 8022394402 Enrollment ID: I20170419002381 |
News Archive
Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.
Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.
Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.
The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.
› Verified 4 days ago
Provider Name | Elizabeth R Chambers |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1780180752 PECOS PAC ID: 0749543189 Enrollment ID: I20180417001147 |
News Archive
Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.
Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.
Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.
The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.
› Verified 4 days ago
Provider Name | Dawn R Lowrance |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1295219558 PECOS PAC ID: 7517219819 Enrollment ID: I20181016000078 |
News Archive
Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.
Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.
Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.
The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.
› Verified 4 days ago
Provider Name | Amanda J Everett |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1518302173 PECOS PAC ID: 9436371465 Enrollment ID: I20200527001122 |
News Archive
Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.
Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.
Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.
The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.
› Verified 4 days ago
Provider Name | Blythe B Otter-bugg |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1598258824 PECOS PAC ID: 6002215118 Enrollment ID: I20210521001706 |
News Archive
Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.
Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.
Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.
The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.
› Verified 4 days ago
Provider Name | Ginger Harbin |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1427631613 PECOS PAC ID: 4082013412 Enrollment ID: I20210604000489 |
News Archive
Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.
Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.
Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.
The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.
› Verified 4 days ago
Provider Name | Jamie L Otter |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1356869101 PECOS PAC ID: 9032519111 Enrollment ID: I20210610002334 |
News Archive
Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.
Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.
Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.
The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.
› Verified 4 days ago
Provider Name | Suzanne C Council |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1124629886 PECOS PAC ID: 8224436530 Enrollment ID: I20211016000045 |
News Archive
Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.
Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.
Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.
The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.
› Verified 4 days ago
Provider Name | Michele Arlene Bagley |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1689312423 PECOS PAC ID: 9032568845 Enrollment ID: I20231205003041 |
News Archive
Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.
Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.
Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.
The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.
› Verified 4 days ago
Provider Name | Tracy Lee Gogan |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1972830826 PECOS PAC ID: 4587013339 Enrollment ID: I20231206000334 |
News Archive
Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.
Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.
Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.
The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.
› Verified 4 days ago
Provider Name | Edwina Wallace |
---|---|
Provider Type | Practitioner - Mental Health Counselor |
Provider Identifiers | NPI Number: 1003382938 PECOS PAC ID: 3577913144 Enrollment ID: I20231221003400 |
News Archive
Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.
Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.
Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.
The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.
› Verified 4 days ago
Provider Name | Lorin Nemrava |
---|---|
Provider Type | Practitioner - Mental Health Counselor |
Provider Identifiers | NPI Number: 1013045228 PECOS PAC ID: 9931550654 Enrollment ID: I20240108000560 |
News Archive
Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.
Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.
Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.
The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.
› Verified 4 days ago
Provider Name | Tonya Fontes |
---|---|
Provider Type | Practitioner - Mental Health Counselor |
Provider Identifiers | NPI Number: 1427321736 PECOS PAC ID: 1254782477 Enrollment ID: I20240111002501 |
News Archive
Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.
Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.
Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.
The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.
› Verified 4 days ago
Provider Name | Dennis B Owens |
---|---|
Provider Type | Practitioner - Mental Health Counselor |
Provider Identifiers | NPI Number: 1508038324 PECOS PAC ID: 6204288541 Enrollment ID: I20240123000459 |
News Archive
Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.
Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.
Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.
The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.
› Verified 4 days ago
Provider Name | Lacey Joy Merchant |
---|---|
Provider Type | Practitioner - Mental Health Counselor |
Provider Identifiers | NPI Number: 1699029082 PECOS PAC ID: 1658717517 Enrollment ID: I20240313003546 |
News Archive
Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.
Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.
Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.
The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.
› Verified 4 days ago
News Archive
Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.
Vanda Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.
Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.
The Griffith University study investigated parasite interactions in wild birds and found they are a crucial indicator of malaria infection risk.
› Verified 4 days ago
Res-care Premier, Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 209 Kings Ln, Battle Creek, MI 49014 Phone: 269-753-0491 | |
Guided Growth Therapy Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 134 Cascade Dr, Battle Creek, MI 49015 Phone: 616-805-9344 | |
Masters Counseling Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 71 S 20th St, Suite 112, Battle Creek, MI 49015 Phone: 269-965-6058 | |
Tammy Cairns Lpc Caadc Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 315 Eaton St, Battle Creek, MI 49017 Phone: 269-967-2367 | |
Peaceful Heart Counseling Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 117 Michigan Ave W, Battle Creek, MI 49017 Phone: 269-967-2760 | |
Spgb Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 32 W Van Buren St, Battle Creek, MI 49017 Phone: 269-964-3830 Fax: 269-964-3833 | |
Christian Counseling Center Of Battle Creek Inc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 601 S Shore Dr Unit 224, Battle Creek, MI 49014 Phone: 269-979-8119 Fax: 269-979-8124 |